Drawing for ASTA MEDICA

USPTO serial 75523630

ASTA MEDICA

Reviewed by CopyMark Law Group

Reg. 2432606Status 710
Filing date
Status date
Registration date
Mar 6, 2001
Examiner
WILLIAMS KELLY L.
Law office
SCANNING ON DEMAND

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with ASTA MEDICA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

ROBERT G WEILACHER

ROBERT G WEILACHER BEVERIDGE DEGRANDI WEILACHER & YOUNG LLP1850 M ST NW STE 800WASHINGTON, DC 20036UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001CHEMICALS, NAMELY, PHARMACEUTICAL ACTIVE AND AUXILIARY COMPOSITIONS FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS, COSMETICS AND PERSONAL CARE PRODUCTSSECTION 8 - CANCELLED—
003COSMETICS; NAMELY, PERFUME, BODY LOTIONS, SKIN LOTIONS AND CREAMS, BATH AND TOILET SOAPS, CREAM BATH, SHAMPOOS, HAIR LOTIONS, DENTIFRICES, THROAT SPRAYS AND MOUTH WASHES FOR NON-MEDICAL USE AND BREATH FRESHENERSSECTION 8 - CANCELLED—
005PHARMACEUTICAL PREPARATIONS; NAMELY, ANORECTICS FOR THE TREATMENT OF ANOREXIA, ANALGESICS/ANTIRHEUMATICS FOR THE TREATMENT OF PAINS, ANTIALLERGICS FOR THE TREATMENT OF ALLERGIC DISEASES, ANTIDOTES FOR THE TREATMENT OF TOXICITY AND POISONING, ANTIEMETICS/ANTIVERTIGINUOSICS FOR THE TREATMENT OF HYPEREMESIS, VOMITING, MOTION SICKNESS, ANTIHYPERTONICS/ANTIHYPERTENSIVES FOR THE TREATMENT OF HYPERTENSION, ANTITUSSIVES/EXPECTORANTS FOR THE TREATMENT OF ALL KINDS OF COUGHS AND MUCOUS DISEASES, BALNEOTHERAPEUTICS FOR THE TREATMENT OF DERMATOPATHY, DERMATITIS, BETABLOCKERS USED IN THE FIELD OF CARDIAC AND CARDIOVASCULAR DISEASES ACE-INHIBITORS USED IN THE TREATMENT OF CARDIAC AND CARDIOVASCULAR DISEASES, BRONCHOLYTICS/ANTIASTHMATICS USED IN THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT, DERMATICS USED IN THE FIELD OF ALL KINDS OF DERMATIC DISEASES, DIAGNOSTIC REAGENTS FOR MEDICAL CLINICAL AND MEDICAL LABORATORY USE, DIURETICS FOR THE TREATMENT OF DIURESIS AND HYPERTENSION, CARDIOACTIVE AGENTS USED FOR THE TREATMENT OF CARDIAC AND CARDIOVASCULAR DISEASES, CORONARY AGENTS/VASODILATORS FOR USE IN THE TREATMENT OF CORONARY HEART DISEASES, HEPATICA AGENTS FOR USE IN THE TREATMENT OF HEPATIC DISEASES, GASTROINTESTINAL AGENTS FOR USE IN THE TREATMENT OF GASTROINTESTINAL DISEASES, MIGRAINE AGENTS FOR USE IN THE TREATMENT OF MIGRAINES AND HEADACHES, PHARMACEUTICAL PREPARATIONS FOR MOUTH AND THROAT THERAPEUTIC PURPOSES, MUSCLE RELAXANTS, PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF OPTHALMIC DISEASES; PREPARATIONS FOR THE TREATMENT OF PARKINSON'S DISEASE AND AGAINST EXTRA PYRAMIDAL DISORDERS, PSYCHOTROPIC DRUGS FOR THE TREATMENT OF PSYCHOTROPIC AND PSYCHOTIC DISEASES, RHINILOGICS FOR USE IN THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT, THYROID THERAPEUTICS, SERA FOR CLINICAL OR MEDICAL LABORATORY USE, IMMUNOGLOBINS FOR CLINICAL OR MEDICAL LABORATORY USE; VACCINES FOR USE IN THE PREVENTION OF VIRAL INFLUENZA FOR HUMAN USE; SEXUAL HORMONES AND THEIR INHIBITORS, CYTOSTATIC AGENTS FOR USE IN THE TREATMENT OF CANCER, ONCOSIS AND CARCINOLYSIS, VITAMIN AND MINERAL SUPPLEMENTS, AND PHYTOTHERAPEUTICS FOR USE IN THE TREATMENT OF ALL KINDS OF INFLAMMATORY DISEASES AS WELL AS DERMATIC DISEASES, INHALERS FILLED WITH PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES, IN VITRO DIAGNOSTIC PREPARATIONS FOR MEDICAL CLINICAL AND MEDICAL LABORATORY USESECTION 8 - CANCELLED—
010INHALERS FOR THERAPEUTIC PURPOSES SOLD EMPTYSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 8, 2007C8..CANCELLED SEC. 8 (6-YR)—
Dec 1, 2006CFITCASE FILE IN TICRS—
Mar 6, 2001R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 12, 2000PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 10, 2000NPUBNOTICE OF PUBLICATION—
Jul 18, 2000CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 7, 2000CNEAEXAMINER'S AMENDMENT MAILED—
Jul 7, 2000DOCKASSIGNED TO EXAMINER—
Jun 24, 2000DOCKASSIGNED TO EXAMINER—
Mar 20, 2000CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 10, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 28, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 2, 1999CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 19, 1999DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance